ABT 202 - Anbogen Therapeutics
Alternative Names: ABT-202 - Anbogen TherapeuticsLatest Information Update: 03 Nov 2022
At a glance
- Originator AnBogen Therapeutics
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 21 Sep 2022 Early research in Cancer in Taiwan (unspecified route) (Anbogen Therapeutics Pipeline, September 2022)
- 21 Sep 2022 Anbogen Therapeutics plans for IND-enabling studies for Cancer by 2025 (Anbogen Therapeutics Pipeline, September 2022)